A Study of Everolimus in Combination With Imatinib in Metastatic Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00402662
Recruitment Status : Terminated (unexpected level of toxicity)
First Posted : November 22, 2006
Last Update Posted : December 18, 2013
Information provided by (Responsible Party):
Yale University

Brief Summary:
The purpose of this study is to determine if the combination of everolimus and imatinib will slow the growth of or cause a reduction in the size of the cancer, and to determine the side effects of the combination in patients with melanoma. Each of the drugs in this combination, if used alone, would not be expected to have an effect against the cancer. However, when used together, there is a possibility that they could work together to damage the cancer cells, or to block the formation or function of the blood vessels that feed the cancer, either of which could result in slowing the growth of or shrinking the cancer. Both drugs work by blocking signals that are sent from outside of a cell to the inside of the cell that direct the cell to make certain substances to keep the cell alive. Cancer cells or blood vessels that feed cancer cells may be more sensitive to drugs that block these signals.

Condition or disease Intervention/treatment Phase
Metastatic Melanoma Drug: everolimus Drug: Imatinib Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 3 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of Everolimus in Combination With Imatinib in Metastatic Melanoma
Study Start Date : February 2006
Actual Primary Completion Date : June 2006
Actual Study Completion Date : June 2006

Primary Outcome Measures :
  1. Response rate (as defined by RECIST)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must have histologically confirmed stage III unresectable or stage IV metastatic melanoma. Patients must have measurable disease as defined by RECIST criteria.
  • Patients with up to 1 prior cytotoxic regimen for metastatic disease will be eligible. There will be no prior limitation on adjuvant therapies for stage II/III disease or for patients with stage IV disease treated after resection of all metastatic disease. There will be no prior limitation on biological or hormonal therapies (immune therapies, interferon, hypomethylating agents, histone deacetylase inhibitors, etc.), however, patients previously treated with mTOR inhibitors will be excluded. Prior treatment for metastatic disease is not required. Patients must have recovered from the acute toxicities of prior treatment. Chronic toxicities must have recovered to ≤ grade 1. The minimum interval between prior treatment and first day of dosing on this trial is as follows: standard cytotoxic agents and radiation therapy, 21 days; mitomycin and nitrosoureas, 6 weeks; hormonal and immunotherapy agents, 2 weeks; minor surgery, 2 weeks, major surgery, 3 weeks; investigational agents 4-weeks.
  • Age >18 years. Because no dosing or adverse event data are currently available on the use of everolimus in combination with imatinib in patients <18 years of age, children are excluded from this study, but will be eligible for future pediatric phase 1 combination trials.
  • ECOG performance status < 1.
  • Life expectancy of greater than 3 months.
  • Patients must have organ and marrow function as defined below:
  • Leukocytes >3,000/μL; Absolute neutrophil count >1,500/ μL; platelets >100,000/ μL; Hemoglobin ≥ 9.0 gm/dL (may be transfused to this level); PT/PTT < 1.5x upper limit of normal; Total bilirubin ≤ 2.0 mg/dL;AST(SGOT)/ALT(SGPT) <3X institutional upper limit of normal; Creatinine ≤ 2.0 mg/dL or creatinine clearance >50 mL/min/1.73m2
  • The effects of everolimus and imatinib on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (barrier method of birth control; abstinence) prior to study entry, for the duration of study participation and 3 months after stopping study drug. Should a woman (or the partner of a man participating in this trial) become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
  • Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  • Patients may not be receiving any other investigational agents. Patients may not have received prior treatment for their cancer with an mTOR inhibitor.
  • Patients with known brain metastases or leptomeningeal disease are excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events. Patients with previously treated brain metastases, who no longer require steroids, and have no evidence of progression for at least 8 weeks following treatment of known brain metastases, are eligible.
  • Baseline diastolic blood pressure > 95 mmHg. Blood pressure medications may be used to bring the diastolic pressure to levels acceptable for protocol enrollment.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, ventricular cardiac arrhythmia, myocardial infarction within the previous 6 months, dyspnea at rest, active GI bleeding or ulcer disease, diabetes mellitus, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Pregnant women are excluded from this study because everolimus and imatinib are agents with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with everolimus and imatinib, breastfeeding should be discontinued if the mother is treated on this protocol. These potential risks may also apply to other agents used in this study.
  • Known HIV-positive patients, because of the potential for pharmacokinetic interactions with everolimus and imatinib, and because the potential immunosuppressive actions of everolimus may increase progression or infectious complications of HIV. Appropriate studies will be undertaken in HIV-positive patients when indicated.
  • Patients receiving warfarin (see section 5.2), or chronic treatment with steroids or another immunosuppressive agent. In addition, patients requiring the following agents are excluded from the study, and must not take the agents while on the trial: ketoconazole, itraconazole, erythromycin, clarithromycin, dexamethasone, phenytoin, carbamazepine, rifampin, Phenobarbital, St. John's Wort, simvastatin, other HMG-CoA reductase inhibitors (if metabolized by CYP3A4), cyclosporine, pimozide, triazolo-benzodiazepines, dihydropyridine calcium channel blockers, and acetaminophen or acetaminophen containing products such as Percoset or Vicodin. Patients taking CYP3A4 interacting agents with narrow therapeutic windows will be excluded from the trial.
  • Patient is < 5 years free of another primary malignancy except: if the other primary malignancy is not currently clinically significant nor requiring active intervention, or if other primary malignancy is a basal cell skin cancer or a cervical carcinoma in situ. Existence of any other malignant disease is not a allowed.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00402662

United States, Connecticut
Yale Comprehensive Cancer Center at Yale University School of Medicine
New Haven, Connecticut, United States, 06520-8028
Sponsors and Collaborators
Yale University
Principal Investigator: Mario Sznol, M.D. Yale University

Responsible Party: Yale University Identifier: NCT00402662     History of Changes
Other Study ID Numbers: 0508000541
First Posted: November 22, 2006    Key Record Dates
Last Update Posted: December 18, 2013
Last Verified: December 2013

Keywords provided by Yale University:

Additional relevant MeSH terms:
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas
Imatinib Mesylate
Antineoplastic Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antifungal Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action